THE TREND
(Boursier.com) — The CAC40 is expected to rise to start this first session of a shortened week. The announcement of a further relaxation of health restrictions against the coronavirus in China despite the outbreak of contamination should indeed allow the Paris market to start again on Tuesday while Wall Street ended in the green on Friday after a series of quite contrasting data.
The Chinese authorities have therefore decided to lift, as of January 8, the mandatory anti-Covid-19 quarantine for anyone entering its territory. The disease has also been downgraded to category B, such as anthrax or AIDS, whereas until now it was managed according to a category A protocol, such as cholera and bubonic plague. And rumors about new support measures for the local economy are circulating in trading rooms.
Something to relax the atmosphere to start this last week of the year which promises to be very calm in the absence of many speakers (several places including London are still closed today). Business news is logically sparse and the macro agenda is hardly fuller with a few second-tier indicators to watch in the United States.
Finally, note the return of the barrel of Brent to the $85 mark this morning. The evolution of Chinese health policy and the risks of continued disruption of production in the United States following the winter storm are indeed supporting crude prices.
WALL STREET
Wall Street ended Friday’s session up slightly ahead of a three-day long Christmas weekend… The S&P500 finally recovered 0.59% to 3,844 points, the Dow Jones gained 0.53% to 33,203 points, and the Nasdaq regained 0.21% to 10,497 points. On Thursday, the upward revision of US growth in the third quarter, from 2.9% to 3.2%, reinforced concerns about the continuation of monetary tightening by the Fed, especially as the price index Core PCE, the Federal Reserve’s preferred inflation measure, was also revised to 4.7% on an annual basis, compared to the announced 4.6% the previous month.
ECO AND CURRENCIES
France :
– Job seekers registered with Pôle Emploi. (12:00)
UNITED STATES :
– Stocks and wholesale sales. (2:30 p.m.)
– FHFA index of US house prices. (3:00 p.m.)
– S&P Corelogic Case-Shiller house price index. (3:00 p.m.)
– Dallas Fed Manufacturing Index. (4:30 p.m.)
VALUES TO FOLLOW
* Metavisio has just opened a 100% subsidiary in New Delhi in order to participate in Indian government public tenders and also distribute its computers to the general public in stores or on the Internet. The group also announced on Friday that it was ending its discussions with SPAC SportsTek Acquisition. The two companies have “ended their exclusive negotiations and will not sign the contractual documents relating to the business combination. Metavisio shares will therefore remain listed on Euronext Growth in Paris”…
And he indicates this morning to continue to discuss with several strategic partners in the United States in order to develop on the American market, the world’s leading market for computers and tablets, and to list Metavisio on an American stock exchange (NASDAQ or NYSE). Indeed Metavisio already generates 5% of its turnover in the United States, which is unique for a French computer hardware company, but this country should have a? term represent the largest share of the company’s turnover.
* METabolic Explorer announced the signing, on December 23, of an agreement with its main partners to secure the liquidity needed to execute the Group’s strategy and the 2023-2024 industrial transformation plan. This Agreement incorporates new financing enabling the Group to make the first investments needed to deploy its strategy without delay, to boost the sales forces, and to gradually resume production at the METEX NØØVISTAGO plant in Amiens, in order to guarantee its customers a local supply of amino acids and low-carbon functional solutions.
* Nanobiotix announces that a first patient has been randomized in the United States in the NANORAY-312 trial, a global Phase 3 trial evaluating NBTXR3 in the treatment of elderly patients with locally advanced squamous cell carcinoma of the head and neck who are not eligible for platinum-based chemotherapy. NBTXR3 activated by radiotherapy will be evaluated alone or in combination with cetuximab. NBTXR3 is a potentially first-in-class radioenhancer with broad application in solid tumors, with priority given to head and neck cancer.